NCT07231952

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

A Phase II Study of Time-limited Combination of Pirtobrutinib, Venetoclax, and Rituximab in Treatment Naïve Patients With Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) (PRoVen)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)

Conditions

• Waldenstrom Macroglobulinemia
• Lymphoplasmacytic Lymphoma

Interventions

Type	Name	Description
DRUG	Pirtobrutinib	PO QD
DRUG	Venetoclax	PO QD
DRUG	Rituximab	IV or SC

Timeline

• Start date: 2025-11-11
• Primary completion: 2028-04-11
• Completion: 2028-04-11
• First posted: 2025-11-17
• Last updated: 2025-11-17

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study